

BMT CTN #0501 Data Submission - Documentation for Outcomes Dataset

Outcomes dataset has 128 variables for 224 patients on BMT protocol #0501 and each patient has one record.

Notes in the last column of the table below are provided by the BMT CTN DCC to facilitate a better understanding of the submitted datasets:

- **CRF** indicates this variable is from an EMMES Case Report Form, as reported by the transplant center. The name of the CRF is shown for easy reference.
- **EMMES** indicates this variable is from EMMES Enrollment System, as study implemented per protocol.
- **RECODE** indicates this variable is from computation for analysis purposes based on other data source. Algorithm and computation method are provided for reference.
- **ERC** indicates this variable is from the BMT #0501 Endpoint Review Committee adjudication. ERC adjudicated the data in a blinded manner based on the site-reported data in CRFs as well as some clinical notes from the sites. ERC –adjudicated outcomes should supersede the site-reported data if there would be any discrepancy.
- **CIBMTR** indicates this variable is data retrieval from the CIBTMR data system. CIBMTR data were reviewed by the CIBMTR physicians prior to the data transfer to Emmes DCC.

Variables List

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
1	PROT	Char	5	5.	5.	Protocol	EMMES - this is the protocol identifier for BMT CTN studies
2	PATID	Char	18	18.	18.	Patient ID	EMMES – this is patient identifier that can be used for any data merge between this dataset and other datasets. This is unique for each patient in BMT CTN.
3	PROJID	Char	5	5.	5.	Project ID	EMMES – this is the blinded identifier that should be used for any data merge between this dataset and other datasets. This is unique for each patient in BMT CTN.
4	SITE	Char	5	5.	5.	Site Code	EMMES - the code is unique for each site participating in the BMT CTN.
5	TRTRUE	Char	30	30.	30.	Treatment Assignment	EMMES – this is based on randomization and indicates the assignment upon enrollment.
6	TRTCMPSP	Char	50	50.	50.	Treatment Non-compliance	ERC – this is non-compliant treatment adjudicated by ERC. Missing indicates compliance.
7	ENRLDATE	Num	8	MMDDYY8.	8.	Date of Randomization	EMMES – this is the start date of the patient on this study
8	CBUIFDT	Num	8	MMDDYY8.	8.	CBU Infusion Date	CRF – IFU
9	AGE_TXP	Num	8	8.2		Age at Transplantation	RECODE - this is the computed age of years at transplantation based on DOB on CRF – DEM form
10	ETHNIC	Char	3	\$ETHNICF.	3.	Ethnicity	CRF – DEM
11	GENDER	Char	1	\$GENDERF.		Gender	CRF – DEM

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
12	RACEA	Char	1	\$RACEF.		Patient's Race	RECODE – this is based on race and secondary race reported on CRF – DEM form and combine into several big race categories.
13	CBUWEIGH	Num	8	8.2	7.1	Patient Body Weight at Transplant (kg)	CRF – IFU
14	PRFSTCB	Char	2	\$PSA.	2.	Performance Score at Baseline	CRF – ENROLL
15	PRIMDIS	Char	1	\$PRIMDZF.	1.	Primary Disease	CRF – ENROLL
16	STAGE	Char	2	\$DSSTG.		Disease Stage	RECODE – this is disease stage computed based on AMLDXSTG, ALLDXSTG, BIPDXSTG, MDS DXSTG, CMLDXSTG from CRF – ENROLL
17	DISEASE_RISK	Char	13			Disease Risk	RECODE – this is computed based on CRF – ENROLL primary disease and disease stage
18	TNC1_PRECRYO_KG	Num	8	8.2		Cryopreserved Total Nucleated Cells for Cord Unit 1 (10 ⁷ /kg)	RECODE – this is computed based on patient's weight at transplant and pre-cryopreservation total nucleated cell count for CBU infusion # 1 on CRF - IFU
19	TNC1_POSTTHAW_KG	Num	8	8.2		Infused Total Nucleated Cells for Cord Unit 1 (10 ⁷ /kg)	RECODE – this is computed based on patient's weight at transplant and post-thaw total nucleated cell count for CBU infusion # 1 on CRF - IFU
20	TNC2_PRECRYO_KG	Num	8	8.2		Cryopreserved Total Nucleated Cells for Cord Unit 2 (10 ⁷ /kg)	RECODE – this is computed based on patient's weight at transplant and pre-cryopreservation total nucleated cell count for CBU infusion # 2 on CRF - IFU

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
21	TNC2_POSTTHAW_KG	Num	8	8.2		Infused Total Nucleated Cells for Cord Unit 2 (10 ⁷ /kg)	RECODE – this is computed based on patient's weight at transplant and post-thaw total nucleated cell count for CBU infusion # 2 on CRF - IFU
22	CD341_PRECRYO_KG	Num	8	8.2		Cryopreserved CD34+ Cells for Cord Unit 1 (10 ⁵ /kg)	RECODE – this is computed based on patient's weight at transplant and pre-cryopreservation CD34 cell count for CBU infusion # 1 on CRF - IFU
23	CD341_POSTTHAW_KG	Num	8	8.2		Infused CD34+ Cells for Cord Unit 1 (10 ⁵ /kg)	RECODE – this is computed based on patient's weight at transplant and post-thaw CD34 cell count for CBU infusion # 1 on CRF - IFU
24	CD342_PRECRYO_KG	Num	8	8.2		Cryopreserved CD34+ Cells for Cord Unit 2 (10 ⁵ /kg)	RECODE – this is computed based on patient's weight at transplant and pre-cryopreservation CD34 cell count for CBU infusion # 2 on CRF - IFU
25	CD342_POSTTHAW_KG	Num	8	8.2		Infused CD34+ Cells for Cord Unit 2 (10 ⁵ /kg)	RECODE – this is computed based on patient's weight at transplant and post-thaw CD34 cell count for CBU infusion # 2 on CRF - IFU
26	CRDUHLA1	Num	8	HLA.		HLA Match Score for Cord Unit 1	ERC – this is ERC adjudicated HLA score for cord blood unit 1 based on CRF – CH1, CH2, CH3 and CIBMTR data
27	CRDUHLA2	Num	8	HLA.		HLA Match Score for Cord Unit 2	ERC – this is ERC adjudicated HLA score for cord blood unit 2 based on CRF – CH1, CH2, CH3 and CIBMTR data
28	MINHLA	Num	8	HLA.		Combined HLA Match Score	RECODE – this is the computed HLA matching score based on CIBMTR data (minimum HLA match between the first unit and the recipient or the second unit and the recipient)

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
29	RD1_MISMATCH	Char	1	\$BLD.		ABO Match for Cord Unit 1	RECODE – this is computed based on ABO data for CBU infusion #1 collected through CIBMTR
30	RD2_MISMATCH	Char	1	\$BLD.		ABO Match for Cord Unit 2	RECODE – this is computed based on ABO data for CBU infusion # 2 collected through CIBMTR
31	RECIP_CMV	Char	1	\$CMV.		Recipient's CMV	CIBMTR (Inconclusive and Unknown were not included in multivariate analysis)
32	OSDAY	Num	8			Days of Overall Survival from Randomization	RECODE – this is the days from transplant to the death or last follow up, computed for survival analysis
33	OSMON	Num	8	8.2		Months of Overall Survival from Randomization	RECODE – this is the months from transplant to the death or last follow up, computed for survival analysis
34	OSEVENT	Char	9			Outcome for Overall Survival	RECODE – this is the outcome for overall survival endpoint
35	OSSRVCENS	Num	8			Overall Survival Censor Indicator	RECODE – this is the censor indicator for overall survival endpoint (0=End Study, 1=Death)
36	FUDATE	Num	8	MMDDYY8.		Date of Last Follow Up	RECODE - this is based on the last follow-up date from all available data sources including CRF and ERC adjudication
37	DTHDT	Num	8	MMDDYY8.	8.	Date of Death	CRF – DTH
38	COD_ERC	Num	8	DEATHO.		Primary Cause of Death	ERC – this is adjudicated by ERC on patient's primary cause of death
39	DATRANSP	Num	8	MMDDYY8.	8.	Date of Second Transplant	CRF – FUS
40	PRGRLPDT	Num	8	MMDDYY8.	8.	Date of Disease Progression/Relapse	ERC – this is the date of progression or relapse based on relapse form and adjudicated by ERC

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
41	RELAPSEDAY	Num	8			Days of Relapse from Transplant	RECODE – this is the days from transplant to the death, relapse, or last follow up, computed for cumulative incidence of relapse
42	RELAPSEMON	Num	8	8.2		Months of Relapse from Transplant	RECODE – this is the months from transplant to the death, relapse, or last follow up, computed for cumulative incidence of relapse
43	RELAPSEOUTCOME	Char	9			Outcome from Relapse	RECODE – this is the outcome for relapse
44	RELAPSE_CI	Num	8			Relapse Indicator for Competing Risk	RECODE – this is the indicator for relapse competing risk (0=End Study, 1=Relapse, 2=Death)
45	ANC1DT	Num	8	MMDDYY8.	8.	Date of Neutrophil Recovery	CRF – HEM
46	ANCDAY	Num	8			Days of Neutrophil Recovery from Transplant	RECODE – this is the days of neutrophil recovery, second transplant, death, or last follow up from transplant, computed for cumulative incidence of platelet recovery
47	ANCOUTCOME	Char	9			Outcome for Neutrophil Recovery	RECODE – this is the outcome for neutrophil recovery
48	ANC_CI	Num	8			Neutrophil Recovery Indicator for Competing Risk	RECODE – this is the indicator for neutrophil recovery competing risk (0=End Study, 1=Engraft, 2=Death or Secondary Transplant)
49	PL20KDT	Num	8	MMDDYY8.	8.	Date of Platelet Recovery to 20K	ERC – this is ERC adjudicated date for platelet recovery to 20K based on data obtained from CIBMTR
50	PL50KDT	Num	8	MMDDYY8.	8.	Date of Platelet Recovery to 50K	ERC – this is ERC adjudicated date for platelet recovery to 50K based on data obtained from CIBMTR

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
51	PLT50DAY	Num	8			Days of Platelet Recovery to 50K from Transplant	RECODE – this is the days of platelet recovery to 50K, second transplant, death, or last follow up from transplant, computed for cumulative incidence of platelet recovery
52	PLT50OUTCOME	Char	9			Outcome for Platelet Recovery to 50K	RECODE – this is the outcome for platelet recovery to 50K. this is data reported in the primary manuscript
53	PLT50_CI	Num	8			Platelet Recovery to 50K Indicator for Competing Risk	RECODE – this is the indicator for platelet recovery competing risk (0=End Study, 1=Engraft, 2=Death or Secondary Transplant)
54	AGVH24DT	Num	8	MMDDYY8.	8.	Date of Acute GVHD Grade II-IV	ERC – this is the date of onset of grades II-IV acute GVHD adjudicated by ERC
55	AGVH24DAY	Num	8			Days of Grade II-IV Acute GHVD from Transplant	RECODE – this is the days of grade II-IV acute GVHD onset, second transplant, death, or last follow up from transplant, computed for cumulative incidence of grade II-IV acute GVHD
56	AGVH24OUTCOME	Char	9			Outcome for Grade II-IV Acute GVHD	RECODE – this is the outcome for grade II-IV acute GVHD
57	AGVH24_CI	Num	8			Grade II-IV Acute GVHD Indicator for Competing Risk	RECODE – this is the indicator for grade II-IV acute GHVD competing risk (0=End Study, 1=AGVH24, 2=Death or Secondary Transplant)
58	AGVH34DT	Num	8	MMDDYY8.	8.	Date of Acute GVHD Grade III-IV	ERC – this is the date of onset of grades III-IV acute GVHD adjudicated by ERC

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
59	AGVH34DAY	Num	8			Days of Grade III-IV Acute GVHD from Transplant	RECODE – this is the days of grades III-IV acute GVHD onset, second transplant, death, or last follow up from transplant, computed for cumulative incidence of grade III-IV acute GVHD
60	AGVH34OUTCOME	Char	9			Outcome for Grade III-IV Acute GVHD	RECODE – this is the outcome for grade III-IV acute GVHD
61	AGVH34_CI	Num	8			Grade III-IV Acute GVHD Indicator for Competing Risk	RECODE – this is the indicator for grade II-IV acute GVHD competing risk (0=End Study, 1=AGVH34, 2=Death or Secondary Transplant)
62	MAXAGVHD	Char	1	\$X12126X.	1.	Maximum Acute GVHD Grade	ERC – this is the maximum grade of acute GVHD adjudicated by ERC
63	CGVHDT	Num	8	MMDDYY8.	8.	Chronic GVHD Onset Date	ERC – this is the date of onset of chronic GVHD adjudicated by ERC
64	CGVHDDAY	Num	8			Days of Chronic GVHD from Transplant	RECODE – this is the days of chronic GVHD onset, second transplant, death, or last follow up from transplant, computed for cumulative incidence of chronic GVHD
65	CGVHDMON	Num	8	8.2		Months of Chronic GVHD from Transplant	RECODE – this is the months of chronic GVHD onset, second transplant, death, or last follow up from transplant, computed for cumulative incidence of chronic GVHD
66	CGVHDOUTCOME	Char	9			Outcome for Chronic GVHD	RECODE – this is the outcome for chronic GVHD
67	CGVHD_CI	Num	8			Chronic GVHD Indicator for Competing Risk	RECODE – this is the indicator for chronic GVHD competing risk (0=End Study, 1=CGVHD, 2=Death or Secondary Transplant)

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
68	MAXCGVDT	Num	8	MMDDYY8.	8.	Date of Maximum Chronic GVHD Grade	ERC – this is the date of onset of maximum grade of GVHD adjudicated by ERC
69	MAXCGVHD	Char	1	\$X12127X.	1.	Maximum Chronic GVHD Grade	ERC – this is the maximum grade of chronic GVHD adjudicated by ERC
70	ECGVHDT	Num	8	MMDDYY8.		Date of Extensive Chronic GVHD Onset	RECODE – this is the date of extensive chronic GVHD onset, computed based on MAXCGVDT and MAXCGVHD
71	ECGVHDDAY	Num	8			Days of Extensive Chronic GVHD Onset from Transplant	RECODE – this is the days of extensive chronic GVHD onset, second transplant, death, or last follow up from transplant, computed for cumulative incidence of chronic GVHD
72	ECGVHDMON	Num	8	8.2		Months of Extensive Chronic GVHD Onset from Transplant	RECODE – this is the months of extensive chronic GVHD onset, second transplant, death, or last follow up from transplant, computed for cumulative incidence of chronic GVHD
73	ECGVHDOUTCOME	Char	9			Outcome for Extensive Chronic GVHD	RECODE – this is the outcome for extensive chronic GVHD
74	ECGVHD_CI	Num	8			Extensive Chronic GVHD Indicator for Competing Risk	RECODE – this is the indicator for extensive chronic GHVD competing risk (0=End Study, 1=eCGVHD, 2=Death or Secondary Transplant)
75	DFSDAY_TXP	Num	8			Days of Disease-free Survival from Transplant	RECODE – this is the days from transplant to the death, relapse, or last follow up, computed for survival analysis
76	DFSMON_TXP	Num	8	8.2		Months of Disease-free Survival from Transplant	RECODE – this is the months from transplant to the death, relapse, or last follow up, computed for survival analysis

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
77	DFSEVENT	Char	9			Outcome of Disease-free Survival	RECODE – this is the outcome for disease-free survival endpoint
78	DFSSRVCENS	Num	8			Disease-free Survival Censor Indicator	RECODE – this is the censor indicator for disease-free survival endpoint (0=End Study, 1=Death or Relapse)
79	TRMDAY	Num	8			Days of Treatment-related Mortality from Transplant	RECODE – this is the days from transplant to the death, relapse, or last follow up, computed for cumulative incidence of treatment-related mortality
80	TRMMON	Num	8	8.2		Months of Treatment-related Mortality from Transplant	RECODE – this is the months from transplant to the death, relapse, or last follow up, computed for cumulative incidence of treatment-related mortality
81	TRMOUTCOME	Char	9			Outcome for Treatment-related Mortality	RECODE – this is the outcome for treatment-related mortality
82	TRM_CI	Num	8			Treatment-related Mortality Indicator for Competing Risk	RECODE – this is the indicator for treatment-related mortality competing risk (0=End Study, 1=Death, 2=Relapse)
83	INFSEV	Char	1	\$INFSEV.		Maximum Severity of Infectious Episode	RECODE – this is computed based on patient's infection data reported on CRF – INF
84	AGECAT	Char	1	\$AGEC.		Age Group (<10 vs. >=10)	RECODE – this is computed based on patient's age at randomization
85	ETHNICA	Char	1	\$ETHNICB.		Ethnicity (Hispanic vs. Non-Hispanic)	RECODE – this is dichotomized ethnicity for multivariate analyses
86	PRIMDIS_NEW2	Char	1	\$DS.		Disease Diagnosis (ALL vs. AML vs. Others)	RECODE – this is recoded primary disease for multivariate analyses

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
87	PSCAT	Char	1	\$PSC.		Performance Score (>=90 vs. <90)	RECODE – this is dichotomized performance score for multivariate analyses
88	RACEB	Char	1	\$RACEB.		Race (White vs. Non-white)	RECODE – this is dichotomized race for multivariate analyses
89	HLACAT	Char	1	\$HLAC.		Donor-Recipient HLA Matching (3/6 and 4/6 vs. 5/6 and 6/6)	RECODE – this is dichotomized HLA match score for multivariate analyses
90	OSDAY_2YEAR	Num	8			Days of Overall Survival from Randomization For Multivariate Analysis	RECODE – this is the days from transplant to the death or last follow up, computed for multivariate analysis for overall survival, censored at 2 years
91	OSMON_2YEAR	Num	8	8.2		Months of Overall Survival from Randomization For Multivariate Analysis	RECODE – this is the months from transplant to the death or last follow up, computed for multivariate analysis for overall survival
92	OSSRVCENS_2YEAR	Num	8			Overall Survival Censor Indicator For Multivariate Analysis	RECODE – this is the censor indicator for overall survival endpoint (0=End Study, 1=Death) used in the overall survival multivariate analysis
93	DFSDAY_TXP_2YEAR	Num	8			Days of Disease-free Survival from Transplant For Multivariate Analysis	RECODE – this is the days from transplant to the death, or relapse, or last follow up, computed for multivariate analysis for disease-free survival, censored at 2 years
94	DFSMON_TXP_2YEAR	Num	8	8.2		Months of Disease-free Survival from Transplant For Multivariate Analysis	RECODE – this is the months from transplant to the death, or relapse, or last follow up, computed for multivariate analysis for disease-free survival, censored at 2 years

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
95	DFSSRVCENS_TXP_2YEAR	Num	8			Disease-free Survival Censor Indicator For Multivariate Analysis	RECODE – this is the censor indicator for overall survival endpoint (0=End Study, 1=Death) used in the disease-free survival multivariate analysis
96	CD19IRF_0100	Num	8	6.		CD19 at Day 100 (cells/uL)	CRF – this is CD19+ cells at Day 100 from CRF – IRF
97	CD19IRF_0180	Num	8	6.		CD19 at Day 180 (cells/uL)	CRF – this is CD19+ cells at Day 180 from CRF – IRF
98	CD19IRF_0365	Num	8	6.		CD19 at Day 365 (cells/uL)	CRF – this is CD19+ cells at Day 365 from CRF – IRF
99	CD3IRF_0100	Num	8	6.		CD3 at Day 100 (cells/uL)	CRF – this is CD3 cells at Day 100 from CRF – IRF
100	CD3IRF_0180	Num	8	6.		CD3 at Day 180 (cells/uL)	CRF – this is CD3 cells at Day 180 from CRF – IRF
101	CD3IRF_0365	Num	8	6.		CD3 at Day 365 (cells/uL)	CRF – this is CD3 cells at Day 365 from CRF – IRF
102	CD4IRF_0100	Num	8	6.		CD4 at Day 100 (cells/uL)	CRF – this is CD4 cells at Day 100 from CRF – IRF
103	CD4IRF_0180	Num	8	6.		CD4 at Day 180 (cells/uL)	CRF – this is CD4 cells at Day 180 from CRF – IRF
104	CD4IRF_0365	Num	8	6.		CD4 at Day 365 (cells/uL)	CRF – this is CD4 cells at Day 365 from CRF – IRF
105	CD56IRF_0100	Num	8	6.		CD56+/CD16+ at Day 100 (cells/uL)	CRF – this is CD56+/CD16+ cells at Day 100 from CRF – IRF
106	CD56IRF_0180	Num	8	6.		CD56+/CD16+ at Day 180 (cells/uL)	CRF – this is CD56+/CD16+ cells at Day 180 from CRF – IRF
107	CD56IRF_0365	Num	8	6.		CD56+/CD16+ at Day 365 (cells/uL)	CRF – this is CD56+/CD16+ cells at Day 365 from CRF – IRF

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
108	CD8IRF_0100	Num	8	6.		CD8 at Day 100 (cells/uL)	CRF – this is CD8 cells at Day 100 from CRF – IRF
109	CD8IRF_0180	Num	8	6.		CD8 at Day 180 (cells/uL)	CRF – this is CD8 cells at Day 180 from CRF – IRF
110	CD8IRF_0365	Num	8	6.		CD8 at Day 365 (cells/uL)	CRF – this is CD8 cells at Day 365 from CRF – IRF
111	IGAIRF_0100	Num	8	4.		IgA at Day 100 (mg/dL)	CRF – this is IgA at Day 100 from CRF – IRF
112	IGAIRF_0180	Num	8	4.		IgA at Day 180 (mg/dL)	CRF – this is IgA at Day 180 from CRF – IRF
113	IGAIRF_0365	Num	8	4.		IgA at Day 365 (mg/dL)	CRF – this is IgA at Day 365 from CRF – IRF
114	IGEIRF_0100	Num	8	4.		IgE at Day 100 (IU/mL)	CRF – this is IgG at Day 100 from CRF – IRF
115	IGEIRF_0180	Num	8	4.		IgE at Day 180 (IU/mL)	CRF – this is IgG at Day 180 from CRF – IRF
116	IGEIRF_0365	Num	8	4.		IgE at Day 365 (IU/mL)	CRF – this is IgG at Day 365 from CRF – IRF
117	IGGIRF_0100	Num	8	5.		IgG at Day 100 (mg/dL)	CRF – this is IgM at Day 100 from CRF – IRF
118	IGGIRF_0180	Num	8	5.		IgG at Day 180 (mg/dL)	CRF – this is IgM at Day 180 from CRF – IRF
119	IGGIRF_0365	Num	8	5.		IgG at Day 365 (mg/dL)	CRF – this is IgM cells at Day 365 from CRF – IRF
120	IGMIRF_0100	Num	8	5.		IgM at Day 100 (mg/dL)	CRF – this is IgE at Day 100 from CRF – IRF
121	IGMIRF_0180	Num	8	5.		IgM at Day 180 (mg/dL)	CRF – this is IgE at Day 180 from CRF – IRF

#	Variable	Type	Len	Format	Informat	Label	Data Source/Notes
122	IGMIRF_0365	Num	8	5.		IgM at Day 365 (mg/dL)	CRF – this is IgE at Day 365 from CRF – IRF
123	LMYPHIRF_0100	Num	8	4.		Percent lymphocyte of CD45+ cells at Day 100 (%)	CRF – this is percent lymphocyte of CD45+ cells at Day 100 from CRF – IRF
124	LMYPHIRF_0180	Num	8	4.		Percent lymphocyte of CD45+ cells at Day 180 (%)	CRF – this is percent lymphocyte of CD45+ cells at Day 180 from CRF – IRF
125	LMYPHIRF_0365	Num	8	4.		Percent lymphocyte of CD45+ cells at Day 365 (%)	CRF – this is percent lymphocyte of CD45+ cells at Day 365 from CRF – IRF
126	WBCIRF_0100	Num	8	6.		WBC at Day 100 (10 ⁹ /L)	CRF – this is WBC at Day 100 from CRF – IRF
127	WBCIRF_0180	Num	8	6.		WBC at Day 180 (10 ⁹ /L)	CRF – this is WBC at Day 180 from CRF – IRF
128	WBCIRF_0365	Num	8	6.		WBC at Day 365 (10 ⁹ /L)	CRF – this is WBC at Day 365 from CRF – IRF

Algorithm used for the Recode and ERC Adjudications

Algorithm for Acute GVHD Grade:

- The acute GVHD algorithm calculates the grade based on the organ (skin, GI and liver) stage and etiology/biopsy reported on the weekly GVHD form.
- If none of the etiologies for skin, upper GI, lower GI, or liver are reported as GVHD, then the overall grade is 0
- If multiple etiologies are specified for lower GI or liver, the organ system will be down-staged by 1.
- If an upper GI biopsy is negative, upper GI symptoms are down-staged.
- If GVHD is not listed as an etiology for upper GI then upper GI symptoms are down-staged.
- Each organ contributes to the overall grade; while to get an overall grade, it does not necessarily need all organ symptoms. Different organ/stage determine different grade. Details below:

Acute GVHD Grade	Organ Involvement/stage
Grade 0	No skin rash and No protracted nausea and vomiting and No diarrhea or diarrhea < 500 mL/day and Bilirubin < 2.0 mg/dL
Grade I	Skin rash 25-50% and No diarrhea or diarrhea < 500 mL/day and Bilirubin < 2.0 mg/dL
Grade II	Skin rash >50% or Diarrhea >500 mL/day or Bilirubin 2.0 - 3.0 mg/dL or Persistent nausea/vomiting
Grade III	Skin-No rash to Rash > 50% with Diarrhea > 1000 mL/day or severe abdominal pain or Bilirubin 3.1 – 15 mg/dL
Grade IV	Skin-Generalized Erythroderma with Bullus Formation and Desquamation or Bilirubin > 15 mg/dL

Algorithm for Chronic GVHD: Limited vs Extensive (Definition from CIBMTR forms)

- Limited – localized skin involvement and/or hepatic dysfunction due to chronic GVHD
- Extensive – one or more of the following:
 1. generalized skin involvement; or,
 2. liver histology showing chronic aggressive hepatitis, bridging necrosis or cirrhosis; or,
 3. involvement of eye: Schirmer's test with < 5 mm wetting; or
 4. involvement of minor salivary glands or oral mucosa demonstrated on labial biopsy; or
 5. involvement of any other target organ